Onconetix (ONCO) risk factors, FY2025 10-K

Risks Related to our Financial Position and Need for Capital

1. 01We have incurred significant net losses since inception, have only generated minimal revenue, and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve profitability. Our stock is a highly speculative investment43% rewritten
2. 02There is substantial doubt about our ability to continue as a “going concern,” and we will require substantial additional funding to finance our long-term operations. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate our product or other operations61% rewritten
3. 03Our current liabilities are significant, and if those to whom we owe accounts payable, were to demand payment, we would be unable to pay72% rewritten

Risks Related to the Commercialization of our Product

1. 04The marketing approval processes in the United States are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for Proclarix, our business may be harmed
2. 05We depend entirely on the success of a single product. If we do not successfully commercialize our product or we experience significant delays in doing so, this product may not be profitable32% rewritten
3. 06Obtaining and maintaining regulatory approval of our product in one jurisdiction does not mean that we will be successful in obtaining regulatory approval in other jurisdictions
4. 07Even if we are able to commercialize our product, it may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business
5. 08Our product could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product
6. 09We intend to market our product and product candidates in international markets. In order to market our product in regions such as the EEA, Asia Pacific, and many other foreign jurisdictions, we must obtain separate regulatory approvals
7. 10Company shareholders may not realize a benefit from the Proteomedix acquisitions commensurate with the ownership dilution they have experienced in connection with the transactions49% rewritten
8. 11Disruptions to or significantly increased costs associated with transportation and other distribution channels for Proclarix may adversely affect our margins and profitability
9. 12We are dependent on third parties, including LabCorp, to develop, market, distribute and sell our product
10. 13We may not be able to gain and retain market acceptance for our product
11. 14Proclarix is subject to competition from other prostate cancer diagnostics and larger, well-established companies with substantially greater resources than us
12. 15The commercial success of our in-development and future diagnostic tests and services and our revenue growth depend upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies
13. 16If we fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth
14. 17If we cannot maintain our current relationships, or enter into new relationships, with CROs, universities, clinics, laboratories or tissue sample banks, our revenue prospects could be reduced
15. 18We need to ensure strong product performance and quality to maintain and grow our business
16. 19The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline
17. 20We have a significant customer concentration, with a limited number of customers accounting for a large portion or all of our revenues35% rewritten
18. 21Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic tests and manage our inventory
19. 22The timing of our new product offerings is uncertain
20. 23Our access to samples may hinder our ability to research, develop, and commercialize future products
21. 24Adherence to complex test protocols is required

Risks Related to our Business and Industry

1. 25Our reliance on third parties heightens the risks faced by our business
2. 26We are dependent on third parties to market, distribute and sell our product
3. 27We do not have any manufacturing facilities. We will rely on third-party manufacturers for commercial supply of Proclarix
4. 28Our anticipated future dependence upon others for the manufacture of our product may adversely affect our future profit margins and our ability to commercialize our product on a timely and competitive basis
5. 29Manufacturing risks may adversely affect our ability to manufacture our product and could reduce our gross margin and profitability
6. 30We maintain single supply relationships for certain key components, and our business and operating results could be harmed if supply is restricted or ends or the price of raw materials used in its manufacturing process increases
7. 31We may not be able to manage our manufacturing and supply chain effectively, which would harm our results of operations
8. 32We may in the future have conflicts with our current or future partners or third-party providers that could delay or prevent the commercialization of our current product
9. 33We face an inherent risk of product liability exposure related to the commercialization of our product. Product liability claims may be brought against us by patients, healthcare providers or others using, administering, or selling our product
10. 34We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources
11. 35Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business
12. 36We will need to grow the size of our organization in the future, and we may experience difficulties in managing this growth
13. 37Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel
14. 38We may be adversely affected by natural disasters, pandemics and other catastrophic events, and by man-made problems such as terrorism and acts of war, that could disrupt our business operations and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
15. 39Our employees, independent contractors, principal investigators, consultants, and vendors and engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
16. 40Macroeconomic pressures in the markets in which we operate, including, but not limited to, the current conflicts in Ukraine and the Middle East may alter the ways in which we conduct our business operations and manage our financial capacities
17. 41Economic uncertainty may adversely affect our access to capital, cost of capital and ability to execute our business plan as scheduled
18. 42Conditions in the global economy may adversely affect our business, financial condition and results of operations
19. 43Misconduct and errors by our current and former employees and our third-party service providers could cause a material adverse effect on our business and reputation
20. 44Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services, we could lose customers or market share
21. 45We face competition from many sources, including larger companies, and we may be unable to compete successfully
22. 46Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis
23. 47Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our future sales and profitability
24. 48We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain the personnel necessary for our success
25. 49We have installed, and expect to expand, a number of enterprise software systems that affect a broad range of business processes and functional areas, including systems handling human resources, financial controls and reporting, contract management, regulatory compliance and other infrastructure operations

Risks Related to Our Intellectual Property

1. 50It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. If our patent position does not adequately protect our product and/or product candidates, others could compete against us more directly, which would harm our business, possibly materially
2. 51We have entered into several licenses to support our various programs. Termination of any of these license agreements would have a material adverse impact on our ability to develop and commercialize derived products under each respective agreement
3. 52Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and patent protection could be reduced or eliminated for noncompliance with these requirements
4. 53We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms or at all
5. 54We may infringe the intellectual property rights of others, which may prevent or delay our method and/or product development efforts and stop us from commercializing or increase the costs of commercializing our methods and/or product and/or product candidates
6. 55We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful
7. 56If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the value of our technology and product could be significantly diminished
8. 57We may be subject to claims that our employees or consultants have wrongfully used or disclosed alleged trade secrets
9. 58Our intellectual property may not be sufficient to protect our methods and/or product and/or product candidates from competition, which may negatively affect our business as well as limit our partnership or acquisition appeal
10. 59Intellectual property rights do not necessarily address all potential threats to our competitive advantage and changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product

Risks Related to Healthcare Compliance and Other Regulations

1. 60If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including administrative, civil, and criminal penalties and our business, operations and financial condition could be adversely affected
2. 61Healthcare reform in the United States has been implemented in the past, and we expect further changes to be proposed in the future, leading to potential uncertainty in the healthcare industry. Violations of healthcare laws can have an adverse impact on our ability to advance our product and our operating results40% rewritten
3. 62Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation

Risks Related to Owning our Common Stock

1. 63The market price of our common stock has been extremely volatile and may continue to be highly volatile due to numerous circumstances beyond our control, and stockholders could lose all or part of their investment
2. 64We may be subject to securities litigation, which is expensive and could divert our management’s attention83% rewritten
3. 65We do not yet have effective disclosure controls and procedures, or internal controls over all aspects of our financial reporting. Specifically, we have identified the following control deficiencies which we believe are material weaknesses
4. 66We cannot provide assurances that these weaknesses will be effectively remediated, or that additional material weaknesses will not occur in the future
5. 67An active trading market for our common stock may not develop or be sustained
6. 68Our principal stockholders and management own a significant percentage of our capital stock and will be able to exert a controlling influence over our business affairs and matters submitted to stockholders for approval23% rewritten
7. 69There are no assurances that the Panel will grant the Company’s request for continued listing or an extension to demonstrate compliance. If the Company does not obtain a favorable decision from the Panel, its Common Stock will become subject to delisting
8. 70If our shares become subject to the penny stock rules, it would become more difficult to trade our shares
9. 71Future sales of our shares by existing stockholders could cause our stock price to decline
10. 72The issuance or conversion of common shares or other securities convertible into common shares would result significant dilution in the equity interest of existing shareholders and adversely affect the market price of the common shares86% rewritten
11. 73We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors
12. 74We are subject to increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
13. 75Our management team has limited experience managing a public company
14. 76If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and our trading volume could decline
15. 77Failure in, or security breaches or incidents impacting, our information technology or storage systems could significantly disrupt our operations and our research and development efforts
16. 78Our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control, which may cause our stock price to decline
17. 79These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management
18. 80We do not anticipate paying any cash dividends on our common stock in the foreseeable future and, as such, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future
19. 81A possible “short squeeze” due to a sudden increase in demand of our common stock that largely exceeds supply may lead to price volatility in our common stock

Risks Related to Pending Share Exchange

1. 82We could fail to complete the Realbotix Transactions, or the Realbotix Transactions may be completed on different termsNew
2. 83The issuance of securities would result in significant dilution in the equity interest of existing stockholders and adversely affect the marketplace of our Common StockNew
3. 84Our stockholders may not realize a benefit from the acquisition of Realbotix commensurate with the ownership dilution they will experience in connection with the Realbotix Transactions contemplated by the Share Exchange AgreementNew
4. 85The failure to successfully integrate the businesses of us and Realbotix in the expected timeframe would adversely affect our future resultsNew
5. 86The pending Realbotix Transactions may divert the attention of our managementNew
6. 87Unexpected market disruptions may cause major losses for us not anticipated under the Share Exchange AgreementNew
7. 88Risks associated with changes in the technology industryNew
8. 89We may be unable to protect Realbotix’s intellectual propertyNew
9. 90The business of Realbotix is exposed to cybersecurity risksNew
10. 91We expect to incur significant transaction costs in connection with the Realbotix Transactions38% rewritten